The most commonly reported side effects of aducanumab include amyloid related imaging abnormality-oedema/effusion, amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits, and headache, based on 516 FDA adverse event reports from 2005 to 2025. 2.3% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for aducanumab.
These are voluntary reports and do not establish that aducanumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside aducanumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
49.8% of aducanumab adverse event reports involve female patients and 41.9% involve male patients. The largest age group is elderly at 90%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking aducanumab when the adverse event was reported.
Aducanumab is sold under the brand name Aduhelm.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.